Merck Group spinoff iOnctura will put the $18.7m it raised in the M Ventures-backed round into a clinical trial for its solid tumour therapy.

The inflammatory disease therapy developer emerged from stealth to commercialise research from several Max Planck institutes and LDC.

Scott Brun, who headed AbbVie Ventures until last April, has taken on an R&D advisory role at pharmaceutical company Horizon Therapeutics.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

University of Notre Dame's Idea Center formed two spinouts in 2019 to market topical ulcer treatments and bespoke gifts for university benefactors.

3M, CareFirst BlueCross BlueShield, Lafayette General Health, OSF Healthcare and ProMedica all invested as the healthcare technology provider closed an $11.1m round.

Revolution Medicines, based on research from University of Illinois at Urbana-Champaign, Stanford University and UC Berkeley, has filed for a $100m initial public offering.

Sanofi is in line for an exit as Revolution Medicines files for a $100m initial public offering on the Nasdaq Global Market.

University Hospital Tübingen's liver disease treatment spinout HepaRegenix has raised $21.6m in all following a series B round that featured Novo and Boehringer Ingelheim.